Skip to main content

Table 1 Demographic data of 29 patients and next-generation sequencing results of different samples

From: Different next-generation sequencing pipelines based detection of tumor DNA in cerebrospinal fluid of lung adenocarcinoma cancer patients with leptomeningeal metastases

patient ID Age(years) Sex Mutations detected by NGS in different Sample types (mutation allele fractions) EGFR status in primary tumor by ARMS
plasma ctDNA CSF cfDNA CSF cell FFPE of primary cancer
#1 59 M EGFR L747_E749del (42.5%) EGFR L747_E749del (98.1%) EGFR L747_E749del (37.8%) EGFR L747_E749del (29.2%) EGFR wild-type
#2 54 F No mutation ALK G689R (1.0%) No mutation EGFR L858R (18.8%) EGFR L858R
#3 70 M No mutation No mutation No mutation No mutation EGFR wild-type
#4 53 M No mutation EGFR E746_A750del (44.2%); TP53 R158L (97.8%) EGFR E746_A750del (43.6%); TP53 R158L (77.0%) EGFR E746_A750del (67.4%); TP53 R158L (40.0%) Not available
#5 73 F No mutation EGFR L858R (34.4%) ALK G689R (1.2%); EGFR L858R (7.3%) EGFR L858R (24.1%) Not available
#6 54 M FGFR1 R455H (46.8%) EGFR E746Valfs (7.3%), P753Rfs (11.4%); FGFR1 R455H (33.4%) EGFR E746Valfs (5.9%), P753Rfs (6.1%); Not available EGFR wild-type
#7 48 F EGFR G719S (0.3%) EGFR L858R (5.3%) EGFR L858R (2.4%) Not available EGFR L858R
#8 60 F No mutation No mutation No mutation Not available Not available
#9 35 M EGFR G719S (0.1%) KRAS Q61L (0.1%); TP53 W53* (85.5%) TP53 W53* (45.1%) Not available - Not available
#10 72 F No mutation EGFR L858R (51.8%) EGFR L858R (3.8%) Not available EGFR L858R
#11 50 F No mutation EGFR L858R (41.1%); TP53 D228Valfs (87.9%) EGFR L858R (10.7%); TP53 D228Valfs (12.8%) Not available EGFR L858R
#12 54 F No mutation TP53 V272 M (77.3%); EGFR E746_A750del (25.1%) TP53 V272 M (26.1%); EGFR E746_A750del (19.0%) Not available EGFR 19del
#13 55 M No mutation EGFR E746_A750del (19.2%) Not available EGFR E746_A750del (43.2%) EGFR 19del
#14 46 M No mutation No mutation Not available EGFR E746_A750del (88.0%) EGFR 19del
#15 60 M EGFR T263P (0.19%) EGFR L858R (52.7%) Not available Not available EGFR L858R
#16 67 F No mutation No mutation Not available No mutation EGFR wide-type
#17 55 F No mutation No mutation Not available EGFR E746_A750del (48.0%); TP53 T125 M (60%) EGFR 19del
#18 69 M No mutation No mutation Not available Not available EGFR wide-type
#19 43 F No mutation Not available EGFR E746_A750del (1.2%) Not available EGFR 19del
#20 48 F No mutation Not available Not available No mutation EGFR wide-type
#21 72 F EGFR E746_A750del (17.8%) Not available Not available EGFR E746_A750del (2.7%) EGFR 19del
#22 49 F No mutation Not available Not available EGFR E746_A750del (52.4%) EGFR 19del
#23 49 F TP53 N268 fs* (22.7%) Not available Not available EGFR E746_A750del (34.3%); TP53 N268 fs* (20.8%) Not available
#24 67 F No mutation Not available Not available No mutation EGFR wide-type
#25 68 F EGFR E746_A750del (0.6%) Not available Not available EGFR E746_A750del (88.4%) EGFR 19del
#26 43 F No mutation Not available Not available No mutation EGFR wide-type
#27 66 M No mutation Not available Not available TP53 R280S (38.7%) EGFR L858R
#28 72 M No mutation Not available Not available EGFR L858R (27.6%) EGFR L858R
#29 71 F No mutation Not available Not available No mutation EGFR 19del
Total Tests 29 18 13 19 24
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us